*PRIORITY FUNDING CALL: BioCanRx is pleased to announce that the next call for applications is now open in all of the Catalyst, Enabling, Clinical Trial, and Clinical, Social & Economic Impact (CSEI) programs. At this time, BioCanRx is placing highest priority on the intake of new applications for funding, proposing research activities that would be likely to add value to, facilitate the implementation of, or enhance the translation to clinic of, technologies within the existing BioCanRx portfolio of research investments. The projects contained within the BioCanRx research portfolio are found here. Of important note, new applications will be expected to speak very specifically to the value-add of their proposed research deliverables and the complementarity to support the successful development of BioCanRx technologies or research projects.
Funding timelines: Applicants should be aware that all projects must plan to be completed no later than March 31, 2020. Given this time constraint, it is unlikely that new clinical trial projects will be funded in this next call for proposals, unless the trial is of a small pilot scale AND the applicant(s) can convincingly demonstrate feasibility of completion of the study by March 31, 2020.
Application deadlines: Next LOI submission deadline will be 11:59 am EST on November 1, 2017 invited full applications are anticipated by mid-February (date TBD) for funding to commence by April 1, 2018.
BioCanRx invites researchers and their teams to participate in its open, rolling research funding call. The open call builds on past and ongoing investments in the area of cancer biotherapeutics and aims to strengthen Canada’s ability to develop this emerging and promising area of cancer research.
Are you following CAR-T and other immunotherapy research in Canada? BioCanRx has announced $11 million investment in 16 collaborative research projects in novel therapies to cure cancer, including funding to manufacture the first made-in-Canada CAR-T cells.
OTTAWA, ON – Wednesday, February 15, 2017, 10 a.m. ET – BioCanRx, and its partners, today announced funding for 16 collaborative research projects in novel therapies to cure cancer, including research aimed at developing clinical Chimeric Antigen Receptor modified T cell (CAR-T) manufacturing capabilities in Canada.
- Enabling Studies Program: Capacity building for Chimeric Antigen Receptor (CAR)-modified T cell therapies in Canada https://biocanrx.com/wp-content/uploads/2017/02/Enabling-3-HOLT-dashboard3.pdf
- Clinical, Social and Economic Impact Program: Getting better Outcomes with Chimeric Antigen Receptor T-cell therapy (GO–CART): A BioCanRx Research Excelerator to Safely and Effectively Translate CAR-T Cell Therapy for Hematological Malignancies https://biocanrx.com/wp-content/uploads/2017/02/CSEI-2-Lalu-dashboard-.pdf
BioCanRx is investing in research projects advancing several innovative engineered T cell designs, which will further benefit from this infrastructure and capacity investment, and accelerate delivery of these novel concepts into clinical testing in Canada. This Canadian capacity development will pave the way to enable Canadian patients to access this new technology, and will give Canadian researchers the necessary resources to deliver on their innovations in CAR-T and other engineered T cell platforms. This CAR-T manufacturing initiative is unique in that the Canadian academic community recognized a gap and stepped up to drive Canadian solutions to meet grassroots efforts taking place in the U.S., China and Europe.
To help ensure CAR-T cell therapy is brought to patients safely and effectively, BioCanRx is funding a companion Clinical, Social, and Economic Impact project. It will review the existing base of knowledge and involve patient consultation to design a rigorous CAR-T clinical trial protocol ready to implement once the products are ready for a phase 1 clinical trial.
Travel Awards, Early Bird Rates and Confirmed Speakers Announced for the Summit for Cancer Immunotherapy (Summit4CI) 2017 in Ottawa (June 25-28)
Register NOW to attend the Summit for Cancer Immunotherapy 2017, taking place in Gatineau, Québec, from Sunday, June 25, 2017. Early-bird registration rates end on April 19!
We’re delighted to confirm that Robert Andtbacka (Huntsman Cancer Institute) and Stanley Riddell (Fred Hutchinson Cancer Research Center) will deliver opening keynote presentations after our Welcome Reception on the evening of Sunday, June 25, 2017.
Other distinguished speakers, confirmed to date, include:
• Rebecca Auer, Ottawa Hospital Research Institute
• Donna Albertson, NYU Oral Cancer Center
• John Babcock, Zymeworks
• John Bell, Ottawa Hospital Research Institute
• Jason Berman, Dalhousie University
• Katherine Bonter, McGill University
• Jeanette Boudreau, Dalhousie University
• Tania Bubela, University of Alberta
• Cyrille Cohen, Bar-Ilan University
• Christi Guerrini, Baylor College of Medicine
• Carl Hansen, University of British Columbia
• Robert Holt, University of British Columbia
• Dean Lee, Loma Linda University
• Jeffrey Miller, University of Minnesota
• Brad Nelson, University of British Columbia
• Kunle Odunsi, Roswell Park Cancer Institute
• Eustache Paramithiotis, Caprion Proteomics
• Denis-Claude Roy, Université de Montréal
• Ismael Samudio, The Centre for Drug Research and Development
• Kirk Schultz, University of British Columbia
• Len Seymour, University of Oxford
• Michael Surette, McMaster University
• Simon Turcotte, Université de Montréal
BioCanRx is offering up to 100 travel awards to Highly Qualified Personnel (HQP), defined as undergraduate and graduate students, post-doctoral fellows, research associates, technical and clinical research staff, who submit the strongest abstracts as determined by the Summit4CI Abstract Review Board. To be included in the travel award competition, please submit your abstract by end of day March 1, 2017.
We hope you will be able to join us. To register or find out more, please visit www.cancersummit.ca
BioCanRx funding for proof-of-concept preclinical and early phase studies testing oncology biotherapeutics (next intake: July 29)
BioCanRx’s next intake deadline for letters of intent is July 29, 2016 by 11:59 p.m. ET.
BioCanRx is accepting letters of intent for the following four research programs:
- Clinical Trials Program
- Enabling Studies Program
- Catalyst Program
- Clinical, Social and Economic Impact Program
For research program details and more information about the open call application process, please visit our website at www.biocanrx.com/application-process/. This funding opportunity is available to any investigator in a Canadian institution that is eligible to receive funding from CIHR, NSERC and SSHRC.
BioCanRx was announced as a Network of Centres of Excellence on December 15, 2014, with a total of $60 million in funding and commitments from the NCE Program and more than 25 partners. Their goals are to:
- To advance four new cancer biotherapies into Canadian-led clinical trials by 2020
- To build a strong and vibrant cancer biotherapeutics community in Canada